Annual report
3750.TEDINET S100W8RO
Period2024-04-01 → 2025-03-31
Filed2025-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Amended by S100WZTN (2025-11-07).
Key figures · 146
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥122m | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥1.6bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥2.1bn | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.3bn | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | −¥807m | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | −¥773m | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | −¥865m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥907m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥862m | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥418m | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥746m | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥2.2bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | −¥1.0bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥2.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥138m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.1bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥78m | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥832m | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥2.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥139m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥3.5bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥5.8bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥14.1bn | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥16.0bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥14.9bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥2.9bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥3.0bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥631m | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥2.8bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥2.7bn | at 2023-03-31v | Cons. | Net assets |
| Net assets / equity | ¥3.7bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥3.5bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥256m | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.0bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥256m | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.0bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥673m | at 2023-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥702m | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.1bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥987m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥40m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥188m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥83m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥23m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥8.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥283m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥216m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥7m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥172m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥7.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥294m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥36m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥151m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-239.7 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.47 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-118.71 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-8.79 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-101.64 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥15.42 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥46.93 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥288.89 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥273.41 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥392.12 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥381.28 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 11.8% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.3% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 17.3% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.9% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 22.3% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | -142.8% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.5% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | -35.6% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | -2.3% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | -23.3% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 10 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 16 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 64 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 63 | at 2022-03-31v | Cons. | Number of employees |
| Employees | 51 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥151m | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥638m | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥465m | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥153m | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥142m | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥237m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥450m | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | −¥2.8bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥587m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥196m | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥212m | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥93m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥3.2bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥3.6bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | −¥3.2bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | −¥3.8bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | −¥737m | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥270m | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥8m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥98m | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥3.3bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥11.9bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥13.0bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥12.8bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥77m | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥106m | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥21m | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥3.2bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥7.0bn | at 2023-03-31v | Standalone | Net assets |
| Net assets / equity | ¥7.7bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥7.2bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥58m | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥534m | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-354.86 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-421.48 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-82.54 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.61 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥0.97 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥30.39 | 2021-04-01 → 2022-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥0.96 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥2.34 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥357.21 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥778.7 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥861.25 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥823.29 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | -195.3% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 90.4% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.5% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.7% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.5% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | -227.3% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | -77.4% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | -10.4% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.8% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 0.2% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 8,929,419 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 8,929,419 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 8,929,419 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 8,929,419 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 8,711,419 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 2 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 2 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 6 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 5 | at 2022-03-31v | Standalone | Number of employees |
| Employees | 5 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 40
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2024-04-01 → 2025-03-31 | ¥8m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2024-04-01 → 2025-03-31 | ¥733,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2025-03-31 | ¥84m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2025-03-31 | −¥274m |
| Medical Asset Managemetreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥10m |
| Medical Asset Managemetreportable segment | employees | at 2025-03-31 | 8 pure |
| Medical Asset Managemetreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥96m |
| Medical Asset Managemetreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥96m |
| Medical Asset Managemetreportable segment | segment assets | at 2025-03-31 | ¥274m |
| Medical Asset Managemetreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥442m |
| Real Asset Managementreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥39m |
| Real Asset Managementreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥27m |
| Real Asset Managementreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥27m |
| Real Asset Managementreportable segment | segment assets | at 2025-03-31 | ¥3.2bn |
| Real Asset Managementreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥91m |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥49m |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥122m |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥122m |
| —segment total | segment assets | at 2025-03-31 | ¥3.5bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | −¥533m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2023-04-01 → 2024-03-31 | ¥528,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-03-31 | ¥682m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | −¥186m |
| Medical Asset Managemetreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥3m |
| Medical Asset Managemetreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥15m |
| Medical Asset Managemetreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥126m |
| Medical Asset Managemetreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥126m |
| Medical Asset Managemetreportable segment | segment assets | at 2024-03-31 | ¥373m |
| Medical Asset Managemetreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥556m |
| Real Asset Managementreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥193m |
| Real Asset Managementreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.4bn |
| Real Asset Managementreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.4bn |
| Real Asset Managementreportable segment | segment assets | at 2024-03-31 | ¥4.8bn |
| Real Asset Managementreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥31m |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥3m |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥208m |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥1.6bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥1.6bn |
| —segment total | segment assets | at 2024-03-31 | ¥5.1bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | −¥587m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,262
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of treasury stock | CurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember | -44000 | JPY |
| Purchase of treasury stock | CurrentYearDuration_NonConsolidatedMember | -44000 | JPY |
| Total changes of items during the period | CurrentYearDuration_NonConsolidatedMember_TreasuryStockMember | -44000 | JPY |
| Total changes of items during the period | CurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember | -3168346000 | JPY |
| Total changes of items during the period | CurrentYearDuration_NonConsolidatedMember_SubscriptionRightsToSharesMember | － | JPY |
| Total changes of items during the period | CurrentYearDuration_NonConsolidatedMember | -3168346000 | JPY |
| Net assets | CurrentYearInstant_NonConsolidatedMember_TreasuryStockMember | -1530000 | JPY |
| Net assets | CurrentYearInstant_NonConsolidatedMember_ShareholdersEquityMember | -190584000 | JPY |
| Net assets | CurrentYearInstant_NonConsolidatedMember_SubscriptionRightsToSharesMember | 211501000 | JPY |
| Net assets | CurrentYearInstant_NonConsolidatedMember | 20917000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)有価証券報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-06-27 | |
| Fiscal year cover page | FilingDateInstant | Original text (Japanese)第21期（自 2024年４月１日 至 2025年３月31日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社サイトリ細胞研究所 | |
| Company name in english cover page | FilingDateInstant | Cytori Cell Research Institute,Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 橋本 征道 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都千代田区麹町二丁目３番３号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03－6261－9067 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)経営企画部長 藤村 剛 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都千代田区麹町二丁目３番３号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03－6261－9067 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)経営企画部長 藤村 剛 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E05443 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 37500 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社サイトリ細胞研究所 | |
| Filer name in english | FilingDateInstant | Cytori Cell Research Institute,Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第三号様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Current fiscal year start date | FilingDateInstant | 2024-04-01 | |
| Current period end date | FilingDateInstant | 2025-03-31 | |
| Type of current period | FilingDateInstant | FY | |
| Current fiscal year end date | FilingDateInstant | 2025-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2023-04-01 | |
| Comparative period end date | FilingDateInstant | 2024-03-31 | |
| Previous fiscal year end date | FilingDateInstant | 2024-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |